Quick Answer
Yubo International Biotech Ltd reported Total Revenue of $12.4 thousand for fiscal year 2025.
Yubo International Biotech Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $12.4K +256.0% |
$3.5K -99.4% |
$604.7K +479.8% |
$104.3K -91.6% |
$1.24M | $0.00 |
| Net Income | -$1.08M +39.2% |
-$1.78M -48.6% |
-$1.20M +0.8% |
-$1.20M +21.9% |
-$1.54M -1051.1% |
-$134.0K +9.5% |
| Diluted EPS | -$0.01 +50.0% |
-$0.02 +80.0% |
-$0.10 | — | — | — |
| Total Assets | $847.1K -44.8% |
$1.53M -7.9% |
$1.67M -29.0% |
$2.35M -48.8% |
$4.59M +458623.3% |
$1.0K -75.0% |
| Cash and Equivalents | — | — | — | — | $27.5K +2651.7% |
$1.0K -75.0% |
| Stockholders Equity | -$1.95M +42.9% |
-$3.42M -85.7% |
-$1.84M -226.1% |
-$565.4K -330.9% |
-$131.2K +92.7% |
-$1.80M -8.1% |
| Operating Income | -$1.19M +32.9% |
-$1.77M -48.1% |
-$1.19M +0.9% |
-$1.21M +21.9% |
-$1.54M -5220.2% |
-$29.0K +39.6% |
| Gross Profit | $8.2K +208.3% |
$2.6K -99.4% |
$419.2K +696.1% |
$52.7K -93.6% |
$820.6K -33.8% |
$1.24M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$310.2K | +50.1% | -34.7% |
| Diluted EPS | September 30, 2025 | $0.00 | +100.0% | — |
| Total Assets | September 30, 2025 | $953.2K | -42.4% | -9.4% |
| Cash and Equivalents | June 30, 2022 | $36.6K | -53.9% | +250.6% |
| Stockholders Equity | September 30, 2025 | -$1.66M | +46.9% | +58.4% |
| Operating Income | September 30, 2025 | -$310.1K | +41.8% | -24.2% |
| Gross Profit | September 30, 2025 | $0.00 | — | — |
- Yubo International Biotech Ltd reported Total Revenue of $12.4 thousand for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +256.0% in Total Revenue compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Net Income of -$1.08 million for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +39.2% in Net Income compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Diluted EPS of $0.01 per share (loss) for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +50.0% in Diluted EPS compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Total Assets of $847.1 thousand for fiscal year 2025.
- Yubo International Biotech Ltd showed a decrease of -44.8% in Total Assets compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Cash and Equivalents of $27.5 thousand for fiscal year 2021.
- Yubo International Biotech Ltd showed a decrease of -98.0% in Cash and Equivalents compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Stockholders Equity of -$1.95 million for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +42.9% in Stockholders Equity compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Operating Income of -$1.19 million for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +32.9% in Operating Income compared to the prior fiscal year.
- Yubo International Biotech Ltd reported Gross Profit of $8.2 thousand for fiscal year 2025.
- Yubo International Biotech Ltd showed an increase of +208.3% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: